The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation

Recruiting now

Conditions studied: Atrial Fibrillation (AF), Mitral Regurgitation, Tricuspid Regurgitation

In brief

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic and can lead to valve regurgitation and a poor prognosis. At present, atrial fibrillation ablation is one of the most effective means for the recurrence of atrial fibrillation in clinical practice, but the recurrence rate is high. Therefore, it is of great significance to find the predictors of relapse after atrial fibrillation ablation for clinical precision treatment. three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation. Therefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.

Key facts

Study ID

NCT07085650

Run by

First Hospital of China Medical University

People needed

2000

Starts

2024-12-30

Expected to finish

2026-09-30

Last updated by the study team

2025-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old;
• Patients who came to the hospital with atrial fibrillation and intended to undergo ablation.

You may not qualify if…

• - History of left atrial or left atrial appendix thrombus, new cerebral infarction and myocardial infarction (< 6 months);
• Congenital heart disease, valvular heart disease, dilated heart disease, hypertrophic cardiomyopathy, pacemaker implantation, artificial valve replacement;
• hyperthyroidism, severe liver and kidney insufficiency;
• Proposed cardiac pacemaker implantation;
• Previous history of catheter ablation;
• The quality of three-dimensional transesophageal images was insufficient and could not be analyzed;
• refuse to sign the informed consent.

Where it is running

• First Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.